Skip to main content
Premium Trial:

Request an Annual Quote

ProKyma Gets $783K for CTC Detection Technology Development

NEW YORK (GenomeWeb News) – UK firm ProKyma today announced a £482,000 ($783,211) grant from the National Institute for Health Research to further develop its technology to detect circulating tumor cells.

The funding will be used by the spinout of the Defence Science and Technology Laboratory — a center of scientific excellence for the Ministry of Defence — to use its KymaSep technology to find a patient's specific cancer mutation.

KymaSep is a portable system based on an injection molded device. The technology automates the manipulation of magnetic particles to purify and concentrate low levels of circulating tumor cells in blood. After purification, the cancer cell can be sequenced, providing information that allows CTC numbers to be measured cost effectively, ProKyma said.

During treatment, CTC numbers should decrease and KymaSep would allow oncologists to change treatments or dosages if the CTC numbers do not go down, ProKyma said, adding that it has spent six years developing the technology.

With the NIHR funding, ProKyma seeks to develop KymaSep to the point where the company can raise Series A funding to manufacture the system by the end of 2014.

ProKyma is collaborating with a multi-disciplinary team "to deliver the challenging technical breakthroughs needed in this project." It has licensed from CellCap Technologies cell capture technology currently being optimized to harvest millions of stem cells for cellular therapies.

Working in collaboration with researchers at the University of Liverpool, ProKyma will adapt the technology for "the very low number of cell captures needed for CTC detection," the company said.

The Liverpool Pancreatic Biomedical Research Unit will optimize the method for capture, sequencing, and enumeration of CTC. The information will then be translated into a device for routine use. The device also will be tested against samples from the Liverpool Cancer Trials Unit to decipher its usefulness in real patient samples.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.